View in EDS

Mirtazapine: a review of its use in major depression and other psychiatric disorders.

Saved in:
Bibliographic Details
Title: Mirtazapine: a review of its use in major depression and other psychiatric disorders.
Authors: Croom KF (AUTHOR), Perry CM (AUTHOR), Plosker GL (AUTHOR), Croom, Katherine F (AUTHOR), Perry, Caroline M (AUTHOR), Plosker, Greg L (AUTHOR)
Source: CNS Drugs. 2009, Vol. 23 Issue 5, p427-452. 26p.
Abstract: Mirtazapine (Remeron, Zispin) is a noradrenergic and specific serotonergic antidepressant (NaSSA) that is approved in many counties for use in the treatment of major depression. Monotherapy with mirtazapine 15-45 mg/day leads to rapid and sustained improvements in depressive symptoms in patients with major depression, including the elderly. It is as effective as other antidepressants and may have a more rapid onset of action than selective serotonin reuptake inhibitors (SSRIs). Furthermore, it may also have a higher sustained remission rate than amitriptyline. Preliminary data suggest that mirtazapine may also be effective in the treatment of anxiety disorders (including post-traumatic stress disorder, panic disorder and social anxiety disorder), obsessive-compulsive disorder, undifferentiated somatoform disorder and, as add-on therapy, in schizophrenia, although large, well designed trials are needed to confirm these findings. Mirtazapine is generally well tolerated in patients with depression. In conclusion, mirtazapine is an effective antidepressant for the treatment of major depression and also has the potential to be of use in other psychiatric indications. [ABSTRACT FROM AUTHOR]
Copyright of CNS Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 105536691
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Mirtazapine: a review of its use in major depression and other psychiatric disorders.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Croom+KF%22">Croom KF</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Perry+CM%22">Perry CM</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Plosker+GL%22">Plosker GL</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Croom%2C+Katherine+F%22">Croom, Katherine F</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Perry%2C+Caroline+M%22">Perry, Caroline M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Plosker%2C+Greg+L%22">Plosker, Greg L</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22CNS+Drugs%22">CNS Drugs</searchLink>. 2009, Vol. 23 Issue 5, p427-452. 26p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Mirtazapine (Remeron, Zispin) is a noradrenergic and specific serotonergic antidepressant (NaSSA) that is approved in many counties for use in the treatment of major depression. Monotherapy with mirtazapine 15-45 mg/day leads to rapid and sustained improvements in depressive symptoms in patients with major depression, including the elderly. It is as effective as other antidepressants and may have a more rapid onset of action than selective serotonin reuptake inhibitors (SSRIs). Furthermore, it may also have a higher sustained remission rate than amitriptyline. Preliminary data suggest that mirtazapine may also be effective in the treatment of anxiety disorders (including post-traumatic stress disorder, panic disorder and social anxiety disorder), obsessive-compulsive disorder, undifferentiated somatoform disorder and, as add-on therapy, in schizophrenia, although large, well designed trials are needed to confirm these findings. Mirtazapine is generally well tolerated in patients with depression. In conclusion, mirtazapine is an effective antidepressant for the treatment of major depression and also has the potential to be of use in other psychiatric indications. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of CNS Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=105536691
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2165/00023210-200923050-00006
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 26
        StartPage: 427
    Titles:
      – TitleFull: Mirtazapine: a review of its use in major depression and other psychiatric disorders.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Croom KF
      – PersonEntity:
          Name:
            NameFull: Perry CM
      – PersonEntity:
          Name:
            NameFull: Plosker GL
      – PersonEntity:
          Name:
            NameFull: Croom, Katherine F
      – PersonEntity:
          Name:
            NameFull: Perry, Caroline M
      – PersonEntity:
          Name:
            NameFull: Plosker, Greg L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2009
              Type: published
              Y: 2009
          Identifiers:
            – Type: issn-print
              Value: 11727047
          Numbering:
            – Type: volume
              Value: 23
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: CNS Drugs
              Type: main
ResultId 1